|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400093773 |
|
最近更新日期: Date of Last Refreshed on: |
2024-12-11 16:58:54 |
|
注册时间: Date of Registration: |
2024-12-11 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
多组学策略探讨肠道普雷沃氏菌介导苍附导痰汤改善痰湿型PCOS患者代谢紊乱及子代早期发育宫内环境的机制研究 |
|
Public title: |
Exploring the mechanism of intestinal Prevotella mediated Cangfu Daotan decoction in improving metabolic disorders and early development of offspring in patients with phlegm dampness type PCOS through multi omics strategies |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
多组学策略探讨肠道普雷沃氏菌介导苍附导痰汤改善痰湿型PCOS患者代谢紊乱及子代早期发育宫内环境的机制研究 |
|
Scientific title: |
Exploring the mechanism of intestinal Prevotella mediated Cangfu Daotan decoction in improving metabolic disorders and early development of offspring in patients with phlegm dampness type PCOS through multi omics strategies |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
江美燕 |
研究负责人: |
刘爱霞; 金雪静 |
|
Applicant: |
Meiyan Jiang |
Study leader: |
Aixia Liu; Xuejing Jin |
|
申请注册联系人电话: Applicant telephone: |
+86 158 5718 4844 |
研究负责人电话: Study leader's telephone: |
+86 138 5801 0974 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jymzxb@163.com |
研究负责人电子邮件: Study leader's E-mail: |
liuaixia@zju.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
浙江省杭州市上城区鲲鹏路369号 |
研究负责人通讯地址: |
浙江省杭州市学士路1号;浙江省杭州市上城区鲲鹏路369号 |
|
Applicant address: |
No. 369, Kunpeng Road, Shangcheng District, Hangzhou, Zhejiang Province |
Study leader's address: |
No. 1, Bachelor Road, Hangzhou, Zhejiang Province; No. 369, Kunpeng Road, Shangcheng District, Hangzhou, Zhejiang Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
杭州市妇产科医院 |
||
|
Applicant's institution: |
Hangzhou Obstetrics and Gynecology Hospital |
||
|
研究负责人所在单位: |
浙江大学医学院附属妇产科医院;杭州市妇产科医院 |
||
|
Affiliation of the Leader: |
Obstetrics and Gynecology Hospital, Zhejiang University School of Medicine; Hangzhou Obstetrics and Gynecology Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
IRB-20240255-R; [2024]医伦审A第(056)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
浙江大学医学院附属妇产科医院临床研究伦理委员会; 杭州市妇产科医院伦理委员会 |
||
|
Name of the ethic committee: |
Clinical Research Ethics Committee of Obstetrics and Gynecology Hospital Affiliated to Zhejiang University School of Medicine,Ethics Committee of Hangzhou Obstetrics and Gynecology Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-04-09 00:00:00 |
||
|
伦理委员会联系人: |
金孙 |
||
|
Contact Name of the ethic committee: |
Sun Jin |
||
|
伦理委员会联系地址: |
浙江省杭州市学士路1号 |
||
|
Contact Address of the ethic committee: |
No.1 Xueshi Road, Hangzhou City, Zhejiang Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 571 5600 5430 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
杭州市妇产科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Hangzhou Obstetrics and Gynecology Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浙江省杭州市上城区鲲鹏路369号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 369, Kunpeng Road, Shangcheng District, Hangzhou,zhejiang Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
政府资助和联合资助 |
||||||||||||||||||||||
|
Source(s) of funding: |
Government qualifications and joint funding |
||||||||||||||||||||||
|
Target disease: |
Polycystic ovary syndrome |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
(1) 采集 PCOS 患者临床数据(包括中医辩证临床症候 、一般资料 、代谢指标 、IVF-ET 妊娠结局等); 收取临床标本建立痰湿型 PCOS 临床样本库; 多组学方法分析 PCOS 患者 粪便肠道菌群图谱及变化轨迹;完成糖脂代谢和子宫局部细胞功能相关的肠道微生物组的功 能的相关性分析 。揭示 PCOS 肠道靶菌及菌群代谢对疾病的致病作用; (2)探讨分析苍附导痰汤对 PCOS 患者的疗效评估,并联合微生物组学和代谢组学探究 苍附导痰汤对 PCOS 的作用机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) Collect clinical data of PCOS patients (including TCM dialectical clinical symptoms, general information, metabolic indicators, IVF-ET pregnancy outcomes, etc.); Collect clinical specimens and establish a clinical sample bank for phlegm dampness type PCOS; Multi omics methods were used to analyze the fecal gut microbiota profile and trajectory changes in PCOS patients; Conduct a correlation analysis of the gut microbiome function related to glucose and lipid metabolism and local uterine cell function. Revealing the pathogenic role of PCOS intestinal target bacteria and microbiota metabolism in the disease; (2) Explore and analyze the therapeutic effect of Cangfu Daotan Tang on patients with PCOS, and combine microbiology and metabolomics to explore the mechanism of action of Cangfu Daotan Tang on PCOS. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1)年龄20-40岁; 2)自伦理申请通过-2026年12月本院就诊的患者; 3)有生育需求; 4)根据2003年鹿特丹标准诊断为PCOS; 5)参照《中医妇科学》辨证为痰湿证。 |
||||||||||||||||||||||
|
Inclusion criteria |
1) Age 20-40 years old; 2) Patients who have been admitted to our hospital in December 2026 after the approval of the ethics application; 3) have the need to have children; 4) diagnosis of PCOS according to the 2003 Rotterdam criteria; 5) Refer to the "Gynecology of Traditional Chinese Medicine" for phlegm-dampness syndrome. |
||||||||||||||||||||||
|
排除标准: |
1)所有研究对象均无肝肾疾病,无甲状腺、心脑血管疾病,无高血压、糖尿病; 2)近3个月内无使用激素类药物病史。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) All study subjects had no liver and kidney diseases, no thyroid, cardiovascular and cerebrovascular diseases, no hypertension, and no diabetes; 2) No history of hormone use in the past 3 months. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-12-15 00:00:00至 To 2025-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-12-15 00:00:00 至 To 2025-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究对象分为实验组(痰湿型多囊卵巢综合征患者),按照电脑产生的数字随机分为实验组1,给与苍附导痰汤150ml,早晚各1次口服;实验组2给予二甲双胍0.5g,早晚各1次,口服;对照组为输卵管阻塞或者慢性输卵管炎患者,不给予任何干预措施。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The research subjects were divided into experimental group (patients with phlegm dampness type polycystic ovary syndrome), and randomly divided into experimental group 1 according to computer-generated numbers. They were given 150ml of Cangfu Daotan decoction orally once in the morning and once in the evening; Experimental group 2 was given 0.5g metformin orally, once in the morning and once in the evening; Experimental group 3 did not receive any intervention measures; The control group consisted of patients with tubal obstruction or chronic salpingitis, who were not given any intervention measures. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
临床试验公共管理平台ResMan(www.medresman.org),共享数据时间:2025-02-01 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan (www.medresman.org), a public management platform for clinical trials, data sharing time: 2025-02-01 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统(Electronic Data Capture, EDC) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture (EDC) system |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |